INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. concerning allegations of securities fraud and unlawful business practices related to its drug ELEVIDYS [1][2]. Group 1: Lawsuit Details - The lawsuit involves claims that Sarepta and certain officers/directors engaged in securities fraud or other unlawful practices [2]. - Investors who purchased Sarepta securities during the Class Period have until August 25, 2025, to request appointment as Lead Plaintiff [2]. Group 2: Impact of ELEVIDYS - On March 18, 2025, Sarepta reported the death of a patient with Duchenne muscular dystrophy after treatment with ELEVIDYS, leading to a stock price drop of $27.81 (27.44%) to $73.54 [4]. - Following a request from EU authorities for a review of the death, Sarepta halted recruitment and dosing in some clinical studies, resulting in a further stock decline of $4.18 (7.13%) to $54.43 on April 4, 2025 [5]. - A second fatality from acute liver failure was reported on June 15, 2025, prompting Sarepta to halt its clinical trial and suspend distribution of ELEVIDYS, causing a significant stock drop of $15.24 (42.12%) to $20.94 [6]. - The FDA issued a Safety Communication on June 24, 2025, regarding the investigation of acute liver failure risks associated with ELEVIDYS, leading to a stock price decrease of $1.52 (8.01%) to $17.46 [7].